Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients

Anaesthesia and Intensive Care

Volumn 39, Issue 6, 2011, Pages 1030-1037

  Chung, J ^a,b   Oh, J M ^a,c   Cho, E M ^a   Jang, H J ^d   Hong, S B ^a   Lim, C M ^a   Koh, Y S ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Department of Pharmacy ^*  (South Korea)

^c Seoul National University   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

Critically ill; Methicillin resistant Staphylococcus aureus; MRSA; Pneumonia; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PROSPECTIVE STUDY; ADOLESCENT; AGED; APACHE; AREA UNDER THE CURVE; CRITICAL ILLNESS; DOSE RESPONSE; HALF LIFE TIME; INTENSIVE CARE; KIDNEY; KIDNEY FUNCTION TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; STAPHYLOCOCCAL PNEUMONIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; AREA UNDER CURVE; COHORT STUDIES; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INTENSIVE CARE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; PROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84855372379     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1103900608     Document Type: Article

References (32)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520-532.
2. Ho PL; Hong Kong intensive care unit antimicrobial resistance study (HK-ICARE) Group. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant Gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med 2003; 31:1175-1182.
3. Theaker C, Ormond-Walshe S, Azadian B, Soni N. MRSA in the critically ill. J Hosp Infect 2001; 48:98-102. (Pubitemid 32700708)
4. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639-644.
5. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 2001; 61:1-7. (Pubitemid 32108318)
6. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490. (Pubitemid 34553708)
7. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-1177. (Pubitemid 30265635)
8. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-2235. (Pubitemid 35231593)
9. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286. (Pubitemid 23046569)
10. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006; 26:539-550.
11. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42:S35-39. (Pubitemid 41832063)
12. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467. (Pubitemid 32801896)
13. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-869. (Pubitemid 26413723)
14. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15:85-91.
15. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
16. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-942. (Pubitemid 39447034)
17. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-955. (Pubitemid 44583720)
18. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144. (Pubitemid 44631403)
19. Thomson Micromedex. Micromedex healthcare series: DRUGDEX system. Greenwood Village, CO: Thomson Micromedex; 2008.
20. Lacy C, Armstrong L, Goldman M, Lance L: Drug information handbook, 17th ed. Hudson, OH: LEXI-COMP 2008.
21. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques. Chest 1992; 102:S553-556.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
23. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394. (Pubitemid 38375611)
24. Caglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008; 32:294-301.
25. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562-577.
26. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 47:147-152.
27. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance - what's dosing got to do with it? Crit Care Med 2008; 36:2433-2440.
28. Jung YJ, Koh Y, Hong SB, Chung JW, Ho Choi S, Kim NJ et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38:175-180.
29. Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011; 37:639-647.
30. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-514.
31. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-1115. (Pubitemid 47208584)
32. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37:95-101.